TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases

M Gonciarz reports grants and personal fees from Takeda, Janssen, Sandoz, Roche and Bristol Myers Squib. P Leszczyński reports grants and personal fees from AbbVie, Roche, UCB, Lilly, Novartis, Bristol Myers Squibb, Amgen, Janssen, Abivax and Viela Bio outside the submitted work. W Owczarek worked as a consultant or speaker and participated as a principal investigator researcher in clinical trials sponsored by AbbVie, Alfasigma, Almirall, Bioderma, Bristol Myers Squibb, Egis, Eli Lilly, Galenica, Galderma, Janssen-Cilag, Leo Pharma, medac GmbH, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz and Teva Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

The authors thank J Monk and D P Figgitt from Content Ed Net for providing medical writing assistance in the development of this manuscript, with funding from Bristol Myers Squibb.

留言 (0)

沒有登入
gif